Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 2-mer - AB 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 47460.65 
• Atom Count: 3334 
• Residue Count: 436 
• Unique protein chains: 2

5FHB

Crystal Structure of Protective Ebola Virus Antibody 100

• DOI: 10.2210/pdb5FHB/pdb

• Classification: IMMUNE SYSTEM
• Expression System: Homo sapiens


• Deposited: 2015-12-21 Released: 2016-03-16 
• Deposition Author(s): Gilman, M.S.A., McLellan, J.S.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.973 Å
• R-Value Free: 0.194 
• R-Value Work: 0.159 

Literature

Structural and molecular basis for Ebola virus neutralization by protective human antibodies.

Misasi, J., Gilman, M.S., Kanekiyo, M., Gui, M., Cagigi, A., Mulangu, S., Corti, D., Ledgerwood, J.E., Lanzavecchia, A., Cunningham, J., Muyembe-Tamfun, J.J., Baxa, U., Graham, B.S., Xiang, Y., Sullivan, N.J., McLellan, J.S.

(2016) Science 351: 1343-1346

• PubMed: 26917592 
• DOI: 10.1126/science.aad6117
• Primary Citation of Related Structures:  
  5FHC, 5FHA


• PubMed Abstract: 
  

Ebola virus causes hemorrhagic fever with a high case fatality rate for which there is no approved therapy. Two human monoclonal antibodies, mAb100 and mAb114, in combination, protect nonhuman primates against all signs of Ebola virus disease, including viremia. Here, we demonstrate that mAb100 recognizes the base of the Ebola virus glycoprotein (GP) trimer, occludes access to the cathepsin-cleavage loop, and prevents the proteolytic cleavage of GP that is required for virus entry. We show that mAb114 interacts with the glycan cap and inner chalice of GP, remains associated after proteolytic removal of the glycan cap, and inhibits binding of cleaved GP to its receptor. These results define the basis of neutralization for two protective antibodies and may facilitate development of therapies and vaccines.

---

Organizational Affiliation: 

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Division of Infectious Diseases, Boston Children's Hospital, Boston, MA 02215, USA.

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Antibody 100 Fab heavy chain	H	228	N/A	Mutation(s): 0
Protein Feature View is not available: No corresponding UniProt sequence found.

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details
Antibody 100 Fab light chain	L	208	N/A	Mutation(s): 0
Protein Feature View is not available: No corresponding UniProt sequence found.

Small Molecules

Ligands 2 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
ACT	H, L	ACETATE ION C2 H3 O2 QTBSBXVTEAMEQO-UHFFFAOYSA-M
EDO	H, L	1,2-ETHANEDIOL ETHYLENE GLYCOL C2 H6 O2 LYCAIKOWRPUZTN-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.973 Å
• R-Value Free: 0.194 
• R-Value Work: 0.159 
• Space Group: P 3₂ 2 1
• Diffraction Data DOI: 
  10.15785/SBGRID/249 SBGrid

Unit Cell:

Length (Å)	Angle (°)
a = 71.540	α = 90.00
b = 71.540	β = 90.00
c = 199.012	γ = 120.00

Software Package:

Software Name	Purpose
PHENIX	refinement
Aimless	data scaling
MOSFLM	data reduction
PHASER	phasing
Coot	model building
PDB_EXTRACT	data extraction

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2015-12-21 
• Released Date: 2016-03-16 
• Deposition Author(s): Gilman, M.S.A., McLellan, J.S.

Revision History 

• Version 1.0: 2016-03-16
  Type: Initial release
• Version 1.1: 2016-03-30
  Type: Database references